Sign In
Buy NNVC
$1.31
-0.0100 (-0.758%)
At Close: Jun 23, 2026
NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387
08:48am, Monday, 19'th Aug 2024
NanoViricides (NYSE-A:NNVC) is advancing its clinical program with plans for an innovative Phase II trial of its drug candidate NV-387, the company announced Monday. The drug candidate NV-387, which h
SHELTON, CT / ACCESSWIRE / August 19, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update
NanoViricides reports major progress in advancing broad-spectrum antiviral drug NV-387
08:37am, Thursday, 08'th Aug 2024
NanoViricides (NYSE-A:NNVC) has highlighted significant progress made in advancing its lead drug candidate NV-387 during the 2024 fiscal year 2024, which ended June 30, in a letter to investors. NV-38
NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
06:30am, Thursday, 08'th Aug 2024
SHELTON, CT / ACCESSWIRE / August 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update o
Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?
07:00am, Friday, 02'nd Aug 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 2, 2024) - Investorideas.com, a go-to investing platform covering biotech and nanotechnology issues a snapshot looking at news
NanoViricides' lead asset for broad spectrum efficacy wins praise in industry reports
08:46am, Thursday, 01'st Aug 2024
NanoViricides (NYSE-A:NNVC) has announced the publication of two independent reports on the company by industry analysts which highlight the potential of its broad spectrum drug candidate NV-387 as a
SHELTON, CT / ACCESSWIRE / August 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports that two separat
NanoViricides spotlights lead drug candidate's potential as COVID therapy
09:09am, Wednesday, 24'th Jul 2024
NanoViricides (NYSE-A:NNVC) has highlighted the strong safety and efficacy of its lead clinical drug candidate NV-387 against coronaviruses. Animal studies of NV-387 have shown it can be “highly eff
NanoViricides discusses lead program and next steps
09:02am, Thursday, 11'th Jul 2024
NanoViricides (NYSE-A:NNVC), a leader in broad-spectrum antiviral nanomedicines, is advancing its development program for NV-387. This single drug has shown activity against various respiratory viral
SHELTON, CT / ACCESSWIRE / July 11, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, discusses its development
NanoViricides hails broad potential of lead antiviral drug as it prepares to begin first Phase II trial
10:57am, Monday, 01'st Jul 2024
NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, highlighted the efficacy of its lead drug, NV-387 against a range of viruses in animal models as it prepares to begin f
NanoViricides hails the potential of NV-387 in combatting bird flu virus H5N1
08:37am, Monday, 24'th Jun 2024
NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, believes its drug NV-387 could be crucial in fighting the bird flu virus H5N1. In recent studies, NV-387 outperformed t
SHELTON, CT / ACCESSWIRE / June 24, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-br
NanoViricides says antiviral drug candidate shows promise in protecting lungs against Influenza A
09:38am, Thursday, 20'th Jun 2024
NanoViricides (NYSE-A:NNVC) announced that its ultra-broad-spectrum antiviral drug candidate NV-387 demonstrated effectiveness in protecting lungs from damage from Influenza A H3N2 in a lethally infe
NanoViricides antiviral candidate 'may be first effective oral nanomedicine'
09:01am, Tuesday, 11'th Jun 2024
NanoViricides (NYSE-A:NNVC) said its lead antiviral candidate, NV-387, was found to be highly active when taken orally, making potentially the first nanomedicine to be effective in this way. NV-387
